These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12921122)

  • 1. Peptide based adsorbers for therapeutic immunoadsorption.
    Rönspeck W; Brinckmann R; Egner R; Gebauer F; Winkler D; Jekow P; Wallukat G; Müller J; Kunze R
    Ther Apher Dial; 2003 Feb; 7(1):91-7. PubMed ID: 12921122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance, clinical effectiveness, and safety of immunoadsorption in a wide range of indications.
    Fuchs K; Rummler S; Ries W; Helmschrott M; Selbach J; Ernst F; Morath C; Gauly A; Atiye S; Stauss-Grabo M; Giefer M
    Ther Apher Dial; 2022 Feb; 26(1):229-241. PubMed ID: 33914397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoadsorption with regenerating systems in neurological disorders --A single center experience.
    Hohenstein B; Passauer J; Ziemssen T; Julius U
    Atheroscler Suppl; 2015 May; 18():119-23. PubMed ID: 25936315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber.
    Lüftl M; Stauber A; Mainka A; Klingel R; Schuler G; Hertl M
    Br J Dermatol; 2003 Sep; 149(3):598-605. PubMed ID: 14510995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoadsorption therapy for dilated cardiomyopathy and pulmonary arterial hypertension.
    Dandel M; Wallukat G; Englert A; Hetzer R
    Atheroscler Suppl; 2013 Jan; 14(1):203-11. PubMed ID: 23357166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immusorba TR and PH.
    Hirata N; Kuriyama T; Yamawaki N
    Ther Apher Dial; 2003 Feb; 7(1):85-90. PubMed ID: 12921121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoadsorption in SLE: three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity.
    Biesenbach P; Schmaldienst S; Smolen JS; Hörl WH; Derfler K; Stummvoll GH
    Atheroscler Suppl; 2009 Dec; 10(5):114-21. PubMed ID: 20129388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ig apheresis for the treatment of severe DCM patients.
    Pokrovsky SN; Ezhov MV; Safarova MS; Saidova MA; Shitov VN; Afanasieva MI; Khaustov AI; Adamova IY; Afanasieva OI; Konovalov GA
    Atheroscler Suppl; 2013 Jan; 14(1):213-8. PubMed ID: 23357167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoadsorption using Immusorba TR and PH.
    Hirano R; Hirata N
    Transfus Apher Sci; 2017 Oct; 56(5):661-665. PubMed ID: 28923775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The first aptamer-apheresis column specifically for clearing blood of β1-receptor autoantibodies.
    Wallukat G; Haberland A; Berg S; Schulz A; Freyse EJ; Dahmen C; Kage A; Dandel M; Vetter R; Salzsieder E; Kreutz R; Schimke I
    Circ J; 2012; 76(10):2449-55. PubMed ID: 22850243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurologic diseases of the central nervous system with pathophysiologically relevant autoantibodies--perspectives for immunoadsorption.
    Klingel R; Heibges A; Fassbender C
    Atheroscler Suppl; 2013 Jan; 14(1):161-5. PubMed ID: 23357159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoadsorption in patients with autoimmune ion channel disorders of the peripheral nervous system.
    Antozzi C
    Atheroscler Suppl; 2013 Jan; 14(1):219-22. PubMed ID: 23357168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoadsorption for connective tissue disease.
    Hohenstein B; Bornstein SR; Aringer M
    Atheroscler Suppl; 2013 Jan; 14(1):185-9. PubMed ID: 23357163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The selective therapeutic apheresis procedures.
    Sanchez AP; Cunard R; Ward DM
    J Clin Apher; 2013 Feb; 28(1):20-9. PubMed ID: 23420592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates.
    Rostaing L; Congy N; Aarnink A; Maggioni S; Allal A; Sallusto F; Game X; Kamar N
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():201-6. PubMed ID: 25894155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific removal of autoantibodies by extracorporeal immunoadsorption ameliorates experimental autoimmune myasthenia gravis.
    Lazaridis K; Dalianoudis I; Baltatzidi V; Tzartos SJ
    J Neuroimmunol; 2017 Nov; 312():24-30. PubMed ID: 28912035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoadsorption can improve cardiac function in transplant candidates with non-ischemic dilated cardiomyopathy associated with diabetes mellitus.
    Dandel M; Englert A; Wallukat G; Riese A; Knosalla C; Stein J; Hetzer R
    Atheroscler Suppl; 2015 May; 18():124-33. PubMed ID: 25936316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoadsorption in dilated cardiomyopathy.
    Dörffel WV; Wallukat G; Baumann G; Felix SB
    Ther Apher; 2000 Jun; 4(3):235-8. PubMed ID: 10910026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoadsorption in steroid-refractory multiple sclerosis: clinical experience in 60 patients.
    Heigl F; Hettich R; Arendt R; Durner J; Koehler J; Mauch E
    Atheroscler Suppl; 2013 Jan; 14(1):167-73. PubMed ID: 23357160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ig-Therasorb immunoadsorption for selective removal of human immunoglobulins in diseases associated with pathogenic antibodies of all classes and IgG subclasses, immune complexes, and fragments of immunoglobulins.
    Koll RA
    Ther Apher; 1998 May; 2(2):147-52. PubMed ID: 10225717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.